Shares of the company fell 40 percent Thursday following a story late Wednesday afternoon by Bloomberg, which reported that a bankruptcy filing was a potential option.
The drugmaker reported top-line data from its Phase III study of terlipressin in hepatorenal syndrome type 1, or HSR-1, a disease with no drug treatment available in the U.S. or Canada that affects 30,000-40,000 people per year.
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.